Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria

This study has been completed.
Sponsor:
Collaborator:
Medicines for Malaria Venture
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00519467
First received: August 20, 2007
Last updated: August 21, 2007
Last verified: August 2007
  Purpose

Drug resistance to a range of antimalarial treatments has become widespread in Africa, South East Asia and South America. Because the rapid spread of drug resistance threatens a public health disaster in these areas of the world and to comply with the WHO-Roll Back Malaria policy of using Artemisinin-based combination therapies (ACT), there is a need to develop new, safe, effective and affordable ACT.

Chlorproguanil-dapsone-artesunate (CDA)is a new ACT that is being developed for the treatment of uncomplicated falciparum malaria in Africa.


Condition Intervention Phase
Malaria
Drug: Chlorproguanil-dapsone-artesunate (CDA)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open, Randomised, Multi-Centre Dose Ranging Phase II Study to Evaluate LAPDAP in Combination With Three Different Doses of Artesunate

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Treatment differences between 1,2, or 4mg/kg artesunate with a fixed dose of Chlorproguanil-dapsone (LAPDAP), as measured by determination of PC90 (time to achieve reduction of parasitaemia by 90% of baseline)

Secondary Outcome Measures:
  • The key secondary efficacy endpoint is parasite viability (the proportion of ring-form parasites developing to schizonts) determined from rich adult data and confirmed with more sparse child data

Enrollment: 120
Study Start Date: June 2003
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presentation to a healthcare facility with probable uncomplicated clinical malaria
  • Adults aged between 18 and 60 years , or children aged between 12 and 120 months
  • Weight between 5 and 85kg
  • Pure [on microscopic grounds] screening P. falciparum parasitaemia in children from 25,000 to 100,000ul-1, or in adults from 10,000 to 100,000ul-1. [The parasitaemia range for adults was originally set at 25,000 to 100,000µl-1 and changed to 10,000 to 100,000µl-1 in protocol amendment 3 dated 05 May 2004]
  • Written or oral witnessed consent obtained from subject, parent or guardian
  • Compliance with the requirements of the protocol which include a hospital stay of 4 days and 3 nights and regular blood samples by finger-prick (children) or via a cannula (adults)
  • A negative pregnancy test for women of child-bearing age on enrolment

Exclusion Criteria:

  • Features of severe/complicated falciparum malaria
  • Known allergy to sulphonamides
  • Evidence of any concomitant infection at the time of presentation (including P. ovale and P. malaria)
  • Any other underlying disease that would compromise the diagnosis and the evaluation of the response to the study medication (including clinical symptoms of immunosuppression, tuberculosis and bacterial infection)
  • Treatment in the 28-days prior to screening with sulfadoxine/pyrimethamine (FANSIDAR, CELOXINE), sulfalene/pyrimethamine (METAKELFIN), mefloquine-sulfadoxinepyrimethamine (FANSIMET), chloroquine* (NIVAQUINE); treatment in the 21-days prior to screening with mefloquine, or 7-days prior to screening with amodiaquine, halofantrine, quinine (full course), atovaquone - proguanil, artemisinins, co-artemether, tetracycline or clindamycin, or treatment for 5 half-lives prior to screening with drugs that have a potential anti-malarial activity (e.g. co-trimoxazole in the previous 60 hours)
  • Use of an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to screening
  • Previous participation in this study
  • A positive pregnancy test at enrolment, women of child-bearing age who do not take a pregnancy test or female subjects who are breast-feeding an infant for the duration of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00519467

Locations
Gambia
GSK Clinical Trials Call Center
Banjul, Gambia, PO Box 273
Malawi
GSK Clinical Trials Call Center
Blantyre, Malawi, PO Box 95
Sponsors and Collaborators
GlaxoSmithKline
Medicines for Malaria Venture
Investigators
Study Director: GSK Clinical Trials, M.D GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00519467     History of Changes
Other Study ID Numbers: SB-714703/003
Study First Received: August 20, 2007
Last Updated: August 21, 2007
Health Authority: Malawi: College of Medicine Research and Ethics Committee

Keywords provided by GlaxoSmithKline:
SB-714703
malaria
chlorproguanil,
dapsone,
artesunate,
CDA,
dose-ranging study

Additional relevant MeSH terms:
Malaria
Protozoan Infections
Parasitic Diseases
Artesunate
Chlorproguanil
Dapsone
Proguanil
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Leprostatic Agents
Anti-Bacterial Agents
Amebicides
Antimetabolites

ClinicalTrials.gov processed this record on August 01, 2014